Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

19 October 2026 : Clinical Research  

[In Press] Prognostic Prediction in Living Donor Liver Transplantation Recipients With Complete Pathological Response of Hepatocellular Carcinoma: Single-Center Development and Korea-Nationwide Multi-Center Validation Studies

Woo-Hyoung Kang ORCID logo1ABCDEF, Shin Hwang ORCID logo1ABCDEF, Chul-Soo Ahn1BCE, Deok-Bog Moon1BCE, Gi-Won Song1BCE, Dong-Hwan Jung ORCID logo1BCE, Gil-Chun Park ORCID logo1BCE, Young-In Yoon1BCE, Kwang-Woong Lee ORCID logo2BC, Jong Man Kim ORCID logo3BC, Dong Jin Joo ORCID logo4BC, Young Kyoung You ORCID logo5BC, Je Ho Ryu6BC, Young Seok Han ORCID logo7BC, Jaehong Jeong ORCID logo8BC

DOI: 10.12659/AOT.954574

Ann Transplant In Press; DOI: 10.12659/AOT.954574  

Available online: 2026-10-19, In Press, Corrected Proof

Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule

Abstract

BACKGROUND
Complete pathological response (CPR) after locoregional treatments (LRTs) predicts better outcomes in patients with hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). This study aimed to find risk factors associated with HCC recurrence in patients with LRT-induced CPR of HCC.
MATERIAL AND METHODS
Prognostic factors were identified from a development cohort of 313 patients from a high-volume single-center LDLT database and validated using a nationwide cohort of 418 patients from the Korean multi-center transplantation registry.
RESULTS
In the development study, 380 LRT sessions were performed on 313 patients, while the validation study included 482 sessions for 418 patients. Cumulative tumor recurrence and overall survival rates in the development study showed recurrence rates of 2.0%, 3.9%, 3.9%, and 4.5% and overall survival rates of 97.1%, 93.5%, 91.4%, and 89.2% at 1, 3, 5, and 10 years, respectively, respectively. In the validation study, tumor recurrence rates were 3.4%, 5.6%, and 7.7%, and overall survival rates were 98.6%, 96.0%, and 93.5% at 1, 3, and 5 years, respectively. Multiplicity of non-viable tumors was identified as a significant risk factor for tumor recurrence (P=0.001; HR=9.83) and overall survival (P=0.021; HR=2.91) in the development study, whereas the composite AFP–PIVKA-II score did not show significance. The validation study confirmed that the multiplicity of non-viable tumors was the only significant risk factor for tumor recurrence (P=0.026; HR=2.47) and overall survival (P=0.017; HR=2.82).
CONCLUSIONS
This study demonstrates that LDLT recipients exhibiting LRT-induced CPR with multiple non-viable tumors constitute a high-risk subgroup and may require intensive posttransplant surveillance.

Keywords: Carcinoma, Hepatocellular; Necrosis; Recurrence; Response Evaluation Criteria in Solid Tumors; Transplantation

In Press

Original article  

Analysis of Factors Influencing the Psychological State of Patients After Autologous Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.953645  

Original article  

Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplan...

Ann Transplant In Press; DOI: 10.12659/AOT.953761  

Clinical Research  

Retrospective Study of Implementation and Outcomes of a Non-Cryopreserved Autologous Hematopoietic Stem Cel...

Ann Transplant In Press; DOI: 10.12659/AOT.954230  

Clinical Research  

Prognostic Prediction in Living Donor Liver Transplantation Recipients With Complete Pathological Response ...

Ann Transplant In Press; DOI: 10.12659/AOT.954574  

Most Viewed Current Articles

24 Aug 2021 : Review article   21,930

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article   18,183

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

22 Nov 2022 : Original article   16,833

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

05 Apr 2022 : Original article   16,744

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358